Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLA
Portfolio Pulse from
Levi & Korsinsky filed a class action securities lawsuit against Intellia Therapeutics, alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting NTLA-3001 research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
April 11, 2025 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Lawsuit alleges securities fraud related to NTLA-3001 program, potentially impacting investor confidence and stock performance
The lawsuit and program discontinuation suggest potential negative market sentiment, likely causing short-term stock price pressure
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100